
Prothena Corporation PLC PRTA.O:
PROTHENA ANNOUNCES PHASE 3 AFFIRM-AL CLINICAL TRIAL FOR BIRTAMIMAB IN PATIENTS WITH AL AMYLOIDOSIS DID NOT MEET PRIMARY ENDPOINT
PROTHENA CORPORATION PLC - TO DISCONTINUE BIRTAMIMAB DEVELOPMENT
PROTHENA CORPORATION PLC - PHASE 3 AFFIRM-AL TRIAL DID NOT MEET PRIMARY ENDPOINT
PROTHENA CORPORATION PLC - SECONDARY ENDPOINTS NOT MET IN AFFIRM-AL TRIAL
PROTHENA CORPORATION PLC - BIRTAMIMAB GENERALLY SAFE AND WELL-TOLERATED
PROTHENA CORPORATION PLC - BOARD TO DECREASE SPEND, EXPECTS WORKFORCE REDUCTION